Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173277 | 0.86 | ALDH1A1 (0.31) | ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL13063974 | 0.86 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL16319995 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL382635 | 0.83 | ALDH1A1 (0.33) | KDM4EPKMALDH1A1TSHR | |
| SCHEMBL13020537 | 0.82 | MMP8 (0.33) | — | |
| SCHEMBL13173686 | 0.81 | — | — | |
| SCHEMBL381957 | 0.79 | MCL1 (0.33) | ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL14115522 | 0.77 | — | — | |
| SCHEMBL16318275 | 0.75 | ALDH1A1 (0.32) | ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL16866505 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2408306-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011005595-A2 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108135-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108135-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | ALIOS BIOPHARMA, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095040-A2 | 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | KDM4E 4071/4885PKM 3252/4885ALDH1A1 941/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | KDM4E 2013/4885PKM 2688/4885ALDH1A1 1405/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | KDM4E 3554/4885PKM 1544/4885ALDH1A1 3343/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | KDM4E 3364/4885PKM 1512/4885ALDH1A1 2902/4885 |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | RNASEL, RNASE1, RNASEH1 | KDM4E 1677/4885PKM 1814/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.